Traders purchased shares of Pfizer Inc. (NYSE:PFE) on weakness during trading on Friday. $125.88 million flowed into the stock on the tick-up and $78.59 million flowed out of the stock on the tick-down, for a money net flow of $47.29 million into the stock. Of all stocks tracked, Pfizer had the 8th highest net in-flow for the day. Pfizer traded down ($0.17) for the day and closed at $34.98

PFE has been the topic of several research analyst reports. Jefferies Group set a $41.50 price objective on Pfizer and gave the company a “buy” rating in a report on Thursday, July 14th. JPMorgan Chase & Co. set a $40.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, August 3rd. Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $34.19 price target on the stock. in a report on Tuesday, April 19th. BMO Capital Markets restated a “buy” rating and set a $40.00 price target on shares of Pfizer in a report on Thursday, July 21st. Finally, TheStreet upgraded Pfizer from a “hold” rating to a “strong-buy” rating in a report on Friday, June 3rd. Ten analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $38.17.

The stock has a 50-day moving average price of $35.89 and a 200 day moving average price of $32.91. The firm has a market capitalization of $212.15 billion and a price-to-earnings ratio of 31.01.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. During the same period in the previous year, the firm posted $0.56 earnings per share. The business had revenue of $13.10 billion for the quarter, compared to analysts’ expectations of $13.01 billion. The firm’s revenue was up 10.9% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post $2.46 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 1st. Stockholders of record on Friday, August 5th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.43%. The ex-dividend date is Wednesday, August 3rd.

In related news, VP Loretta V. Cangialosi sold 86,000 shares of the business’s stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $33.97, for a total value of $2,921,420.00. Following the completion of the sale, the vice president now directly owns 271,663 shares of the company’s stock, valued at $9,228,392.11. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Frank A. Damelio sold 100,000 shares of the business’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $34.49, for a total value of $3,449,000.00. Following the completion of the sale, the executive vice president now directly owns 472,994 shares of the company’s stock, valued at $16,313,563.06. The disclosure for this sale can be found here.

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Advisors LLC raised its stake in shares of Pfizer by 1.2% in the fourth quarter. BlackRock Advisors LLC now owns 41,991,752 shares of the biopharmaceutical company’s stock valued at $1,355,494,000 after buying an additional 502,056 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Pfizer by 16.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 24,378,870 shares of the biopharmaceutical company’s stock valued at $786,951,000 after buying an additional 3,522,873 shares in the last quarter. Swiss National Bank raised its stake in shares of Pfizer by 1.4% in the fourth quarter. Swiss National Bank now owns 12,075,889 shares of the biopharmaceutical company’s stock valued at $389,810,000 after buying an additional 161,900 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Pfizer by 24.7% in the fourth quarter. Jennison Associates LLC now owns 11,912,098 shares of the biopharmaceutical company’s stock valued at $384,523,000 after buying an additional 2,361,977 shares in the last quarter. Finally, TD Asset Management Inc. raised its stake in shares of Pfizer by 0.4% in the fourth quarter. TD Asset Management Inc. now owns 6,391,499 shares of the biopharmaceutical company’s stock valued at $206,318,000 after buying an additional 22,815 shares in the last quarter.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.